Positive Phase II data for bemarituzumab in the treatment of HER2-negative gastric or gastroesophageal junction cancer

Bemarituzumab is a first-in-class antibody targeting FGR2b, overexpressed in around 30% of HER2- gastric cancers. In the double-blind Phase II FIGHT trial, its addition to chemotherapy was associated with prolonged median progression-free survival (9.5 v 7.4 months with placebo).

Source:

Biospace Inc.